Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Staphylokinase non immunogène en bolus unique chez les patients atteints d'un accident vasculaire cérébral ischémique aigu dans les 4,5 à 24 heures suivant l'apparition des symptômes (FRIDA-CT)

10 novembre 2026 mis à jour par: Supergene, LLC

Une étude multicentrique, en double aveugle, randomisée, contrôlée par placebo, sur l'efficacité et la sécurité de la staphylokinase recombinante non immunogène chez des patients atteints d'un accident vasculaire cérébral ischémique aigu dans les 4,5 à 24 heures suivant l'apparition des symptômes (FRIDA-CT)

Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC "SuperGene", Russia) or placebo.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Description détaillée

The current guidelines recommended intravenous thrombolysis as the first-line treatment for acute large vessel occlusion of anterior circulation stroke within 4.5 hours of stroke onset. However, a majority of patients arrive in the hospital outside the 4.5-hour time window, who could not receive intravenous thrombolysis.

In 2020, the non-immunogenic staphylokinase was registered in Russia for the acute ischemic stroke treatment within 4,5 h after the onset of symptoms. In the FRIDA randomized clinical trial the non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus of 10 mg regardless patients' bodyweight, simplifying clinical use. In 2024, the non-immunogenic staphylokinase has been included in the updated Russian clinical guidelines for the acute ischemic stroke treatment.

A rapid (10 s) single bolus of the non-immunogenic staphylokinase in patients with acute ischemic stroke may provide significant advantages over a one-hour alteplase administration in the more rapid reperfusion in the first 24 hours after thrombolysis and a greater number of good functional outcomes. It can be assumed that the non-immunogenic staphylokinase usage in patients with acute ischemic stroke outside the 4.5-hour therapeutic window will lead to the restoration of collateral blood flow in the penumbra in comparison with standard medical management.

Therefore, FRIDA-CT trial is aimed to investigate the efficacy and safety of the non-immunogenic staphylokinase within the time window of 4.5-24 hours, wake-up stroke or no witness stroke in patients who had an acute ischaemic stroke with salvageable tissue due to large vessel occlusion.

In the multicenter, double-blind, randomized, placebo-controlled phase III clinical trial patients who had an acute ischaemic stroke due to anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5-24 hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume <70 mL, mismatch ratio ≥1.8 and mismatch volume ≥15 mL) based on CT perfusion or MRI perfusion-weighted imaging (PWI) will be included and randomised to the non-immunogenic staphylokinase, 10 mg (single bolus) regardless patient's bodyweight or placebo group. Patients who are intended for direct thrombectomy will be excluded from the trial. Follow-up period will be 90 days.

Type d'étude

Interventionnel

Inscription (Estimé)

1050

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Nikolay A. Shamalov, MD, prof
  • Numéro de téléphone: +7 (499) 936-99-37
  • E-mail: shamalovn@gmail.com

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Chelyabinsk, Russie
        • Recrutement
        • Chelyabinsk Regional Clinical Hospital No. 3
        • Contact:
        • Chercheur principal:
          • Dmitry V. Popov, PhD
      • Irkutsk, Russie, 664079
        • Recrutement
        • Irkutsk Regional Clinical Hospital
        • Contact:
        • Chercheur principal:
          • Ivan V. Korobeynikov, PhD
      • Kazan', Russie, 420101
        • Recrutement
        • Interregional Clinical and Diagnostic Center
        • Contact:
        • Chercheur principal:
          • Dina R. Khasanova, MD, Prof
      • Krasnodar, Russie, 350086
        • Recrutement
        • S.V. Ochapovsky Research Institute - Regional Clinical Hospital No. 1
        • Contact:
        • Chercheur principal:
          • Ludmila V. Timchenko, MD, prof
      • Krasnogorsk, Russie, 143408
        • Recrutement
        • Krasnogorsk Clinical Hospital
        • Contact:
          • Svetlana V. Alexandrova
          • Numéro de téléphone: +7 (498) 602-03-73
          • E-mail: clairalex@mail.ru
        • Chercheur principal:
          • Svetlana V. Alexandrova
      • Moscow, Russie, 108814
        • Recrutement
        • Moscow Multidisciplinary Clinical Center "Kommunarka"
        • Contact:
        • Chercheur principal:
          • Denis N. Protsenko, PhD
      • Moscow, Russie, 117997
        • Recrutement
        • N.I. Pirogov Russian National Research Medical University
        • Contact:
        • Chercheur principal:
          • Larisa L. Korsunskaya, MD, Prof
      • Nizhny Novgorod, Russie, 603126
        • Pas encore de recrutement
        • N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
        • Contact:
          • Valentina N. Nesterova, PhD
          • Numéro de téléphone: +7 (831) 438-95-38
          • E-mail: nesterova-78@mail.ru
        • Chercheur principal:
          • Valentina N. Nesterova, PhD
      • Orenburg, Russie
        • Recrutement
        • V.I. Voynov Orenburg Regional Clinical Hospital
        • Contact:
        • Chercheur principal:
          • Alexandr N. Chirkov, PhD
      • Saint Petersburg, Russie, 193079
        • Recrutement
        • St. Petersburg Hospital for War Veterans
        • Contact:
        • Chercheur principal:
          • Maria A. Privalova, PhD
      • Saint Petersburg, Russie, 194291
        • Recrutement
        • Leningradskaya Regional Clinical Hospital
        • Contact:
        • Chercheur principal:
          • Natalya V. Zhukovskaya, MD, prof
      • Solnechnogorsk, Russie, 141508
        • Pas encore de recrutement
        • Solnechnogorsk District Hospital
        • Chercheur principal:
          • Anton G. Koledinsky, MD, PhD
        • Contact:
          • Anton G. Koledinsky, MD, PhD
          • Numéro de téléphone: +7 (496) 264-14-56
          • E-mail: koledant@mail.ru
      • Tver', Russie, 170036
        • Recrutement
        • Tver Regional Clinical Hospital
        • Contact:
          • Ksenia V. Khoroshavina
          • Numéro de téléphone: +7 (482) 277-54-65
          • E-mail: kseniarep@mail.ru
        • Chercheur principal:
          • Ksenia V. Khoroshavina
      • Ulyanovsk, Russie
        • Recrutement
        • Ulyanovsk Regional Clinical Hospital
        • Contact:
        • Chercheur principal:
          • Irina V. Greshnova, PhD
      • Volgograd, Russie, 400138
        • Recrutement
        • City Clinical Hospital of Emergency Medical Care No. 25
        • Contact:
        • Chercheur principal:
          • Eduard A. Ponomarev, MD, prof
      • Yekaterinburg, Russie, 620102
        • Recrutement
        • Sverdlovsk Regional Clinical Hospital No. 1
        • Contact:
        • Chercheur principal:
          • Andrey M. Alasheev, MD, prof
    • Ryazan Oblast
      • Ryazan, Ryazan Oblast, Russie, 390039
        • Pas encore de recrutement
        • Ryazan Regional Clinical Hospital
        • Contact:
        • Chercheur principal:
          • Sergei B. Aksentyev, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Men and women aged 18 years and over;
  2. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
  3. Pre-stroke modified Rankin scale (mRS) score≤1;
  4. Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT/MRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;
  5. Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume <70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;
  6. Alberta Stroke Program Early CT score (ASPECTS) > 6;
  7. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);
  8. The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;
  9. Written informed consent from patients or their legally authorized representatives.

Exclusion Criteria:

  1. Acute ischemic stroke within 4,5 h after symptom onset;
  2. Intended to proceed to endovascular treatment;
  3. Known hypersensitivity to the non-immunogenic staphylokinase;
  4. Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;
  5. Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;
  6. Blood glucose <2.8 or >22.2 mmol/L (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);
  7. Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;
  8. Subarachnoid hemorrhage;
  9. Major bleeding currently or within the past 6 months;
  10. Surgery on the brain or spinal cord in the last 2 months;
  11. Punctures of non-compressible arteries and veins in the last 7 days;
  12. Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;
  13. Platelet count below 100,000/mm3;
  14. Previous stroke or severe traumatic brain injury within 3 months;
  15. Unable to perform CT or MRI;
  16. History of hemorrhagic stroke or stroke of unspecified genesis;
  17. Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);
  18. Concomitant use of indirect oral anticoagulants (warfarin) with INR > 1.7;
  19. Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;
  20. Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).
  21. Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;
  22. Acute pancreatitis;
  23. Bacterial endocarditis, pericarditis;
  24. Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;
  25. Cancer with an increased risk of bleeding;
  26. Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;
  27. Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);
  28. Hemorrhagic diathesis, including renal and hepatic failure;
  29. Data on bleeding or acute trauma (fracture) at the time of examination;
  30. Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Placebo

Placebo

Placebo is given as a single intravenous bolus (within 5-10 seconds) immediately upon randomization

Expérimental: Non-immunogenic staphylokinase

The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

Autres noms:
  • Fortélyzine®

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Excellent functional outcome
Délai: 90 days

The number of patients with excellent functional outcome defined as an mRS score 0-1 at 90 days

90 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Ordinal distribution of mRS
Délai: 90 days

Ordinal distribution of mRS at 90 days

90 days
Functional independence outcome
Délai: 90 days

The number of patients with functional independence defined by an mRS score 0-2 point at 90 days

90 days
NIHSS change from baseline
Délai: 7-14 days

NIHSS median change from baseline on discharge

7-14 days
The rate of improvement on reperfusion
Délai: 24 hours

The number of patients with recanalization of 2 and 3 points on the arterial occlusion scale (rAOL) 24 hours after drug administration according to CT (MRI) angiography, where 0 points - complete occlusion, 3 points - complete recanalization.

24 hours
All-cause mortality
Délai: 90 days

Rate of all-cause mortality within 90 days

90 days
Poor functional outcome
Délai: 90 days

The number of patients with poor functional outcome defined by an mRS score 5-6 point at 90 days

90 days

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Hemorrhagic transformation
Délai: 24 hours

Rate of hemorrhagic transformation according to The Heidelberg Bleeding Classification within 24 hours

24 hours
Symptomatic intracranial hemorrhage
Délai: 24 hours

Rate of symptomatic intracranial hemorrhage (sICH) (as defined by The European Cooperative Acute Stroke Study III criteria [ECASSIII] and Safe Implementation of Thrombolysis in Stroke-Monitoring Study [SITS-MOST]) within 24 hours

24 hours
Major bleeding
Délai: 90 days

Rate of major bleeding at 90 days (as defined by the Bleeding Academic Research Consortium (BARC) scale: type 3 and type 5)

90 days
Serious adverse events (SAEs)
Délai: 90 days

Rate of serious adverse events (SAEs) within 90 days

90 days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Nikolay A. Shamalov, MD, prof, Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
  • Directeur d'études: Sergey S. Markin, MD, prof, LLC "SuperGene"

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

9 juin 2026

Achèvement primaire (Estimé)

1 novembre 2028

Achèvement de l'étude (Estimé)

1 janvier 2029

Dates d'inscription aux études

Première soumission

23 décembre 2025

Première soumission répondant aux critères de contrôle qualité

23 décembre 2025

Première publication (Réel)

8 janvier 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The funder of the study is committed to the responsible sharing of data from FRIDA-CT trail. Data will be provided to any qualified investigator on reasonable request. Deidentified participant data will be available after the publication of the results of the completed study on request to the corresponding author.

Délai de partage IPD

within 90 days after request

Critères d'accès au partage IPD

Proposals will be reviewed and approved by the funder and Data and Safety Monitoring Board. Once the proposal has been approved, data can be transferred through a secure online platform after the signing of a data access agreement and a confidentiality agreement.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner